Posted by Michael Wonder on 08 May 2018
First US drug priced at more than $1 million may be on the horizon
7 May 2018 - New gene therapies that aim to cure haemophilia, a disease affecting the blood's ability to clot, are on the horizon.
In the paradoxical world of drug pricing, the first U.S. price tag exceeding $1 million for a medicine is being contemplated as the nation's agita over the cost of prescription drugs climbs ever higher.
New gene therapies that aim to cure hemophilia, a disease affecting the blood's ability to clot, may carry prices of $1.5 million or more, analysts at Leerink wrote in a research note Monday.
Gene therapies deliver a healthy copy of a gene to make up for a defective one that causes disease, aiming to cure — or at least significantly improve — the malady in just one treatment. Such therapies for haemophilia are in development at drugmakers BioMarin, Spark Therapeutics and UniQure.
